Our Company was originally incorporated as "Anthem Biosciences Private Limited" under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to "Anthem Biosciences Limited" and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.
Major Events and Milestones: 2006 - Incorporation of our Company.
2007 - Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.
2008 - Commencement of the discovery biology services with a fermentation capacity of 2 KL.
2010 - Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.
2013 - Received the first USFDA audit approval for Unit I.
2016 - Set up a high potent lab at Unit I - Bommasandra Facility.
2017 - Our Company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital. - Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. - Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL. - Received the second USFDA audit approval for Unit I.
2018 - Anthem Cellutions (India) Private Limited amalgamated into our Company.
2019 - Received the third USFDA approval for Unit I. - Set up a flow chemistry lab at Unit I.
2020 - Commenced operations in biological facility 2 earmarked for a specific client.
2022 - Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.
2023 - Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II. - Addition of Oligonucleotide lab in Unit I. - Set a cGMP scale continuous flow manufacturing facility for Unit II.
2024 - Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I(1); and first ANVISA audit approval for Unit II(1). - Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects. - Fermentation capacity expanded to 140 KL at Unit II. - Conversion of our Company into a public limited company, under the name "Anthem Biosciences Limited".
2025 - Received the fourth USFDA approval for Unit I.
|